AIA
CORT icon

Avalon Investment & Advisory’s Corcept Therapeutics CORT Stock Holding History

Avalon Investment & Advisory’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-108,123
Closed -$2.77M – 317
2022
Q3 		$2.77M Sell
108,123
-7,053
-6% -$189K 0.09% 149
2022
Q2 		$2.74M Buy
+115,176
New +$2.51M 0.08% 152

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avalon Investment & Advisory's CORT Position: Q4 2022 in Review

Avalon Investment & Advisory sold out of Corcept Therapeutics (CORT) in Q4 2022, closing a stake of 108,123 shares — an estimated $2.77M sold.

Avalon Investment & Advisory first reported a position in CORT in Q2 2022 and held it in 2 quarters. The position peaked at $2.77M in Q3 2022. 243 funds tracked by Wall St. Rank hold CORT as of Q4 2022.

  • Avalon Investment & Advisory reported no remaining Corcept Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Avalon Investment & Advisory sold 108,123 Corcept Therapeutics shares in Q4 2022, an estimated $2.77M.
  • Avalon Investment & Advisory first reported a position in Corcept Therapeutics in Q2 2022 and held it in 2 quarters.
  • Avalon Investment & Advisory's Corcept Therapeutics position peaked at $2.77M in Q3 2022.
  • 243 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2022.

Based on Avalon Investment & Advisory's 13F filing for Q4 2022, filed 13 Feb 2023.